How to buy NanoViricides stock (NNVC)

NanoViricides is a biotechnology business based in the US. NanoViricides shares (NNVC) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $1.51 – an increase of 1.34% over the previous week. NanoViricides employs 7 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy NanoViricides stock

Buy NanoViricides stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

NanoViricides stock price (NYSE MKT: NNVC)

Use our graph to track the performance of NNVC stocks over time.

NanoViricides shares at a glance

• Key figures

Information last updated 2024-11-13.

Latest market close	$1.51
52-week range	$1.00 - $3.59
50-day moving average more info button	$1.50
200-day moving average more info button	$1.63
Wall St. target price	$6.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.70

Is it a good time to buy NanoViricides stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NanoViricides price performance over time

Historical closes compared with the close of $1.51 from 2024-12-24

1 week (2024-12-20)	1.34%
1 month (2024-11-27)	9.42%
3 months (2024-09-27)	4.14%
6 months (2024-06-27)	-12.72%

1 year (2023-12-27)	37.27%
2 years (2022-12-27)	33.63%
3 years (2021-12-27)	3.78
5 years (2019-12-27)	2.64

NanoViricides financials

Gross profit TTM	$0
Return on assets TTM	-35.81%
Return on equity TTM	-63%
Profit margin	0%
Book value	$0.87
Market Capitalization more info button	$18.8 million

TTM: trailing 12 months

NanoViricides share dividends

We're not expecting NanoViricides to pay a dividend over the next 12 months.

Have NanoViricides's shares ever split?

NanoViricides's shares were split on a 1:20 basis on 23 September 2019 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NanoViricides shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NanoViricides shares which in turn could have impacted NanoViricides's share price.

NanoViricides share price volatility

Over the last 12 months, NanoViricides's shares have ranged in value from as little as $1.0001 up to $3.59. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while NanoViricides's is 0.968. This would suggest that NanoViricides's shares are less volatile than average (for this exchange).

NanoViricides overview

NanoViricides, Inc. , a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Frequently asked questions

What percentage of NanoViricides is owned by insiders or institutions?
Currently 4.068% of NanoViricides shares are held by insiders and 9.72% by institutions. How many people work for NanoViricides?
Latest data suggests 7 work at NanoViricides. When does the fiscal year end for NanoViricides?
NanoViricides's fiscal year ends in June. Where is NanoViricides based?
NanoViricides's address is: 1 Controls Drive, Shelton, CT, United States, 06484 What is NanoViricides's ISIN number?
NanoViricides's international securities identification number is: US6300873022 What is NanoViricides's CUSIP number?
NanoViricides's Committee on Uniform Securities Identification Procedures number is: 630087302